A world leader in oncology, Genentech, with estimated 2008 revenues of $13.5 billion, is second only to Amgen (AMGN) among global biotechs. Bold Gambit In recent years, Roche has leaned heavily on Genentech for its success. Genentech drugs …
Bloomberg · 7/21/2008
When they show up on boards, CEOs can get nervous about cutting costs and raising stock prices, and manufacturing sites are ... The same kind of scenario recently played out with biotech Amgen ($AMGN), which last year announced its intent to cut …
Fierce Pharma Manufacturing · 5/5/2015
NEW YORK A federal judge on Wednesday dismissed the U.S. Securities and Exchange Commission's lawsuit accusing two Dubai men of insider trading in Onyx Pharmaceuticals Inc while the cancer drugmaker was mulling a takeover bid by Amgen Inc …
Firstpost · 9/17/2015
In a year when several of his peers won big payoffs for one extraordinary reason or another, Amgen ($AMGN) CEO Robert Bradway earned just ... relocation expenses and stock awards worth almost $7 million.
FiercePharma · ByTracy Staton · 4/6/2015
Levkovich analyzed the fifty largest actively-managed mutual funds, and looked at the top ten stock holdings of each fund. Levkovich then tallied the number of times a single stock appeared in a fund's top ten holdings, and ranked the companies accordingly.
The Business Insider · 6/9/2015
The averages are phony, but the stocks aren't. The death crosses and breakdowns and head and shoulders are scary, but the companies continue to do well, albeit for the most part not as well as before, but a lot of that is manmade: the Fed, the inability of ... · ByJim Cramer · 9/8/2015
The Bottom Line. In the wake of the Amgen (AMGN) bid to buy biotech Micromet (MITI), investors and traders with an appetite for risk might want to consider CytRx Corporation (CYTR) and Sunesis Pharmaceuticals (SNSS) as potential acquisition bets …
Smallcap Network · ByJohn Udovich · 3/22/2012
With half the year almost over, there are many different opinions about how the stock market might finish the year. One thing that both retail and professional investors and traders can agree on is that the choppy market has made it difficult to make money.
The Money Show · 5/29/2014
Shifts in the outlook for interest rates are causing stock prices to be far more volatile than long-run fundamentals. Following a comprehensive review of competitive dynamics in the global banking industry, we upgraded our moat ratings for eight banks to wide. · 6/29/2015
2015 hasn’t been the greatest year for the stock market. A quick glance at the major indices paints this picture; the NASDAQ composite has remained relatively flat, while the DJIA and the S&P 500 are down about 8.5% and 5.5% respectively. Even still ...
Market Intelligence Center · 9/4/2015


AMGen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Locate…
AMGen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, AMGen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Data from: Wikipedia